CL2018000391A1 - Combinaciones farmacéuticas y su uso - Google Patents
Combinaciones farmacéuticas y su usoInfo
- Publication number
- CL2018000391A1 CL2018000391A1 CL2018000391A CL2018000391A CL2018000391A1 CL 2018000391 A1 CL2018000391 A1 CL 2018000391A1 CL 2018000391 A CL2018000391 A CL 2018000391A CL 2018000391 A CL2018000391 A CL 2018000391A CL 2018000391 A1 CL2018000391 A1 CL 2018000391A1
- Authority
- CL
- Chile
- Prior art keywords
- formula
- pharmaceutically acceptable
- disclosure
- treatment
- mdm2 inhibitor
- Prior art date
Links
- 229940083338 MDM2 inhibitor Drugs 0.000 abstract 2
- 239000012819 MDM2-Inhibitor Substances 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 230000002062 proliferating effect Effects 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
<p>LA PRESENTE DIVULGACIÓN SE REFIERE A UNA COMBINACIÓN FARMACÉUTICA, POR EJEMPLO, UN PRODUCTO, QUE COMPRENDE UNA COMBINACIÓN DE (A) UN INHIBIDOR DE MDM2 DE FÓRMULA LO FÓRMULA 11,0 UNA DE SUS SALES FARMACÉUTICAMENTE ACEPTABLES, Y UN INHIBIDOR DE LA VÍA DE PIKC DE FÓRMULA III, FÓRMULA IV, FÓRMULA Y O FÓRMULA VI, O UNA DE SUS SALES FARMACÉUTICAMENTE ACEPTABLES, PARTICULARMENTE, PARA EL USO EN EL TRATAMIENTO O LA PREVENCIÓN DE ENFERMEDADES PROLIFERATIVAS. LA DIVULGACIÓN ADEMÁS SE REFIERE A CORRESPONDIENTES FORMULACIONES FARMACÉUTICAS, USOS, MÉTODOS, COMBINACIONES, SOPORTES DE DATOS Y FORMAS DE REALIZACIÓN DE LA DIVULGACIÓN RELACIONADAS. LA DIVULGACIÓN SE REFIERE ADICIONALMENTE AL USO DE UN INHIBIDOR DE MDM2 DE FÓRMULA I O FÓRMULA II, O UNA DE SUS SALES FARMACÉUTICAMENTE ACEPTABLES, SOLO EN EL TRATAMIENTO DE UNA ENFERMEDAD PROLIFERATIVA.</p>
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562205033P | 2015-08-14 | 2015-08-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2018000391A1 true CL2018000391A1 (es) | 2018-07-13 |
Family
ID=56851653
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2018000391A CL2018000391A1 (es) | 2015-08-14 | 2018-02-13 | Combinaciones farmacéuticas y su uso |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US20180243293A1 (es) |
| EP (1) | EP3334426A2 (es) |
| JP (1) | JP2018522936A (es) |
| KR (1) | KR20180037975A (es) |
| CN (1) | CN107921028A (es) |
| AU (1) | AU2016308704B2 (es) |
| BR (1) | BR112018000496A2 (es) |
| CA (1) | CA2991276A1 (es) |
| CL (1) | CL2018000391A1 (es) |
| HK (1) | HK1249408A1 (es) |
| IL (1) | IL256537A (es) |
| MX (1) | MX2018001903A (es) |
| PH (1) | PH12018500096A1 (es) |
| RU (1) | RU2018108804A (es) |
| WO (1) | WO2017029588A2 (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL3541387T3 (pl) | 2016-11-15 | 2021-10-25 | Novartis Ag | Dawka i schemat dla inhibitorów interakcji hdm2-p53 |
| FI3681503T3 (fi) | 2017-09-12 | 2026-08-13 | Novartis Ag | Proteiinikinaasi C:n estäjiä uveamelanooman hoitoon |
| WO2021102004A1 (en) * | 2019-11-18 | 2021-05-27 | Ideaya Biosciences, Inc. | Dosing regimens for a protein kinase c inhibitor |
| WO2024125543A1 (zh) * | 2022-12-16 | 2024-06-20 | 苏州科睿思制药有限公司 | 达洛色替的晶型及其制备方法和用途 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1253449C (zh) | 2000-11-07 | 2006-04-26 | 诺瓦提斯公司 | 作为蛋白激酶c抑制剂的吲哚基马来酰亚胺衍生物 |
| US8440693B2 (en) | 2009-12-22 | 2013-05-14 | Novartis Ag | Substituted isoquinolinones and quinazolinones |
| ITCO20110027A1 (it) * | 2011-07-21 | 2013-01-22 | Nuovo Pignone Spa | Turbomacchina centrifuga multistadio |
| UY34591A (es) * | 2012-01-26 | 2013-09-02 | Novartis Ag | Compuestos de imidazopirrolidinona |
| KR102283895B1 (ko) * | 2013-12-23 | 2021-07-30 | 노파르티스 아게 | 제약 조합물 |
| AU2014372166B2 (en) * | 2013-12-23 | 2017-10-26 | Novartis Ag | Pharmaceutical combinations |
| JO3589B1 (ar) * | 2014-08-06 | 2020-07-05 | Novartis Ag | مثبطات كيناز البروتين c وطرق استخداماتها |
| CN108348611A (zh) * | 2015-08-28 | 2018-07-31 | 诺华股份有限公司 | 使用pi3k抑制剂和mdm2抑制剂的联合疗法 |
-
2016
- 2016-08-11 KR KR1020187003995A patent/KR20180037975A/ko not_active Withdrawn
- 2016-08-11 CA CA2991276A patent/CA2991276A1/en not_active Abandoned
- 2016-08-11 US US15/751,954 patent/US20180243293A1/en not_active Abandoned
- 2016-08-11 EP EP16758285.7A patent/EP3334426A2/en not_active Withdrawn
- 2016-08-11 BR BR112018000496A patent/BR112018000496A2/pt not_active IP Right Cessation
- 2016-08-11 CN CN201680047789.3A patent/CN107921028A/zh active Pending
- 2016-08-11 JP JP2018507614A patent/JP2018522936A/ja active Pending
- 2016-08-11 WO PCT/IB2016/054841 patent/WO2017029588A2/en not_active Ceased
- 2016-08-11 RU RU2018108804A patent/RU2018108804A/ru not_active Application Discontinuation
- 2016-08-11 MX MX2018001903A patent/MX2018001903A/es unknown
- 2016-08-11 AU AU2016308704A patent/AU2016308704B2/en not_active Expired - Fee Related
- 2016-08-11 HK HK18108028.9A patent/HK1249408A1/zh unknown
-
2017
- 2017-12-25 IL IL256537A patent/IL256537A/en unknown
-
2018
- 2018-01-11 PH PH12018500096A patent/PH12018500096A1/en unknown
- 2018-02-13 CL CL2018000391A patent/CL2018000391A1/es unknown
-
2019
- 2019-08-08 US US16/535,214 patent/US20200246331A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| RU2018108804A (ru) | 2019-09-16 |
| CA2991276A1 (en) | 2017-02-23 |
| CN107921028A (zh) | 2018-04-17 |
| MX2018001903A (es) | 2018-06-20 |
| HK1249408A1 (zh) | 2018-11-02 |
| KR20180037975A (ko) | 2018-04-13 |
| US20200246331A1 (en) | 2020-08-06 |
| JP2018522936A (ja) | 2018-08-16 |
| EP3334426A2 (en) | 2018-06-20 |
| WO2017029588A2 (en) | 2017-02-23 |
| PH12018500096A1 (en) | 2018-07-23 |
| AU2016308704A1 (en) | 2018-02-08 |
| WO2017029588A3 (en) | 2017-04-20 |
| IL256537A (en) | 2018-02-28 |
| AU2016308704B2 (en) | 2019-06-20 |
| BR112018000496A2 (pt) | 2018-09-11 |
| US20180243293A1 (en) | 2018-08-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CR20190301A (es) | Compuestos de amino-triazolopiridina y su uso en el tratamiento del cáncer | |
| MX2018001721A (es) | 5-bromo-2,6-di-(1h-pirazol-1-il) pirimidin-4-amina-para su uso en el tratamiento del cancer. | |
| CL2017000469A1 (es) | Derivados de tetrahidronaftaleno que inhiben la proteina mcl-1 | |
| CO2018004857A2 (es) | Derivados de dihidroimidazopirazinona usados en el tratamiento del cáncer | |
| CL2017001675A1 (es) | Derivados de quinazolina utilizados para tratar el vih | |
| MX2019012847A (es) | Compuestos de c5-anilinoquinazolina y su uso en el tratamiento del cancer. | |
| CL2017000902A1 (es) | Dihidropirrolopiridinas inhibidoras de ror-gamma | |
| ECSP109934A (es) | Compuesto - 946 | |
| UY35455A (es) | Inhibidores tripeptidicos de la epoxicetona proteasa | |
| CL2017000682A1 (es) | Compuestos novedosos de imidazopiridazina y su uso. | |
| GT201600250A (es) | Compuestos de 1, 3, 4- tiadiazol y uso de los mismos para el tratamiento del cáncer | |
| CL2019002900A1 (es) | Análogos de benzoazepina como agentes inhibidores de la tirosina cinasa de bruton. | |
| UY38228A (es) | Compuestos de triazolopirimidina y su uso en el tratamiento del cáncer | |
| MX2017005255A (es) | Derivados de carbazol. | |
| CR20180232A (es) | Macrociclos peptídicos contra acinetobacter baumannii | |
| GT201700058A (es) | Compuestos de 1-alquil-6-oxo-1,6-dihidropiridin-3-ilo y usos de los mismos | |
| DOP2016000297A (es) | Composiciones farmacéuticas útiles para tratar enfermedades infecciosas | |
| CL2017002229A1 (es) | Inhibidores de bace1. | |
| MX2019007950A (es) | Inhibidores tripeptidicos de la epoxicetona proteasa. | |
| CO2019007671A2 (es) | Una composición farmacéutica que comprende un derivado de oxazina y su uso en el tratamiento o la prevención de la enfermedad de alzheimer | |
| ECSP18056196A (es) | Derivados de indano | |
| CU20060219A7 (es) | Formulaciones con liberación controlada de principio activo que contiene vardenafilo | |
| CU23604B7 (es) | Compuestos terapéuticos |